The demand for healthcare and innovation is more intense than ever, as the life expectancy continues to improve due to shift in focus towards lifestyle diseases like cancer, heart disease, diabetes, obesity, chronic kidney damage, stroke and Alzheimer's disease, etc. Currently, the healthcare environment is changing quite rapidly challenging the conventional models and presenting new opportunities for growth. Some of the competing trends include advances in bioscience from genomics to personalized medicine (immunotherapy) and the impact of technology disruption, use of digital data and analytics in healthcare is expected to have far-reaching implications in terms of diagnostics, treatments and delivery of care in the future.
Personalized medicine represents a new dimension in modern medicine encompassing Advanced Therapy Medicinal Products (ATMPs). ATMPs include gene, cell and tissue engineered therapies that possess great scientific promise and are emerging as a novel approach for the treatment of a variety of diseases. ATMPs are highly personalized in nature, which is in contrast with
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Update on the Sleeping Beauty transposon system for therapeutic applications f that needs at least a decade time to pass the clinical trials and only few of them will make it to the market. Close to 1700 (65%) are focused on oncology, 287 (11.1%) in the monogenetic field, 182 (7%) in infectious diseases and 180 (6.9%) in the cardiovascular category. The majority of the gene therapy clinical trials currently involve the usage of viral vectors derived from retroviruses/lentiviruses and adenoviruses (AV)/adeno-associated viruses (AAV). In fact, few of the ATMPs in the market are manufactured using retro/lentiviral and AAV viral vectors (Table 5 ). Viral vectors represent an attractive option for gene therapy approaches because of their intrinsic ability to transfer nucleic acids into the cells during infection f f FIGURE 1 Challenges associated with the development of Advanced Therapy Medicinal Products (ATMPs).
and flexibility (can be easily combined with viral vectors). SB transposon vectors has the potential to surpass the hurdles posed by viral vectors. For instance, in contrast to viral vectors, manufacturing clinical-grade SB transposon plasmids is less time consuming and less expensive that neither requires any skilled labor nor additional biosafety facility than BSL-1. Importantly, the use of SB transposon system involves relatively less stringent regulatory requirements that can be met easily leading to much lesser delays thereby saving time specifically in the medical practice scenario. Right from its resurrection SB transposon system has been constantly engineered to meet the clinical demands in terms of safety, efficacy and toxicity [9, 10] . It has also been widely used in pre-clinical studies for modeling various diseases [10, 16] . Some of the trends include the use of transposase mRNA
The proposed use of SB transposon system for rapid manufacturing of cells.
Shown here is a schematic illustrating the autologous cancer immunotherapy involving manufacturing patient's own cells in realtime at point-of-care utilizing SB transposon system. Briefly, peripheral blood lymphocytes (like CD4+ T cells) isolated from the patient's blood will be subjected for single electroporation and those genetically modified cells will be rapidly infused into patient. The genetically modified cells express relevant cell surface protein (like chimeric antigen receptor or simply CAR) that can recognize and kill the malignant cells by binding to the specific cell surface antigens.
instead of plasmid DNA coupled with the use of transposon-minicircles instead of the transposon plasmid that has greatly reduced the cellar toxicity issues and enhanced the efficacy of the SB transposon system [11] . Although the use of transposase in the form of protein for gene delivery is yet to be established but it represents an approach alternative to mRNA or DNA that requires further studies. Engineering SB transposon system further, for 'targeted gene integration' into site-specific genomic loci will be beneficial as it can impart more control and safety associated with uncontrolled random genomic integrations. The 'in vivo gene therapy strategy' involving, in vivo viral transduction system and SB transposon system is currently being evaluated in pre-clinical phase that represents a significant technical advancement as it has the potential to surpass the technical difficulties associated with the collection and ex vivo manufacturing of cells. If this approach translates for human applications in the future it can make the entire gene therapy process easy and robust but further characterization and improvement is needed [12] [13] [14] . In addition, as a fail-safe mechanism, the use of controllable switches (for example RheoSwitch technology) in combination with SB transposon system to regulate transgene expression could instill more control and safety for gene therapy approaches (like CAR-T based immunotherapy). The gene therapy strategy utilizing SB transposon system for the treatment of exudative age-related macular degeneration (AMD) involves a short manufacturing period where retinal cells are engineered and transplanted back to the patient rapidly [4] . In the future, similar strategy involving SB transposon system can be utilized to very rapidly manufacture CAR-T cells within a day or two at the point of care (Figure 2) [15] . Beyond that, SB transposon system is also being evaluated for the development of adoptive cell transfer (ACT)-based immunotherapies to express T-cell receptors (TCRs) for the treatment of solid tumors that represents significant leap in the field of personalized immunotherapy [18] . Overall, in contrast to the viral vector mediated ATMPs, SB transposon based ATMPs can be less expensive and affordable for both payers and insurers and may reach the market soon following clinical trial evaluation. It is encouraging that SB transposon mediated immunotherapies are starting to yield promising results in patients with hematological malignancies, which will likely herald an exciting new era in gene therapy. 
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